#	Pagina
attuale pagina	/open-h2020/projects/194104/index.html

Opendata, web and dolomites

openMedicine

openMedicine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Outcomes and
results

openMedicine project word cloud

Explore the words cloud of the openMedicine project. It provides you a very rough idea of what is the project "openMedicine" about.

health issue pharmacological 25 definition global competent therapeutic epsos unambiguous respect mss interoperable gs1 expert pharmaceutical cross mps regulatory mapping risks sdos cen investigates transfer phc34 harmonise idmp recommendations professionals description serious hl7 concise stage pharmacokinetic policy lasts assure identification industry workshops team border acceptance attributes mp eprescriptions mou solved prescribed map data meta track network usa rules wps dispensed csa univocal ema duty practicability medicinal vocabulary situation message wp5 models substitution develops wp1 clinical national healthcare ihtsdo framework meetings agencies standards solutions actions communication f2f safety post considering experts explores link ms core iso ehealth practices innovation stakeholders scenarios beneficiaries wp3 expanding options implementability patients economic wp4 trust encountered roadmap efforts conceptual road implementations abroad validated indications

Project "openMedicine" data sheet

The following table provides information about the project.

Coordinator	EMPIRICA GESELLSCHAFT FUR KOMMUNIKATIONS UND TECHNOLOGIEFORSCHUNG MBH Organization address address: OXFORDSTRASSE 2 city: BONN postcode: 53111 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Project website	http://www.open-medicine.eu
Total cost	997˙938 €
EC max contribution	997˙938 € (100%)
Programme	1. H2020-EU.3.1.5. (Methods and data)
Code Call	H2020-PHC-2014-single-stage
Funding Scheme	CSA
Starting year	2015
Duration (year-month-day)	from 2015-01-01 to 2016-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	EMPIRICA GESELLSCHAFT FUR KOMMUNIKATIONS UND TECHNOLOGIEFORSCHUNG MBH EMPIRICA GESELLSCHAFT FUR KOMMUNIKATIONS UND TECHNOLOGIEFORSCHUNG MBH Organization address address: OXFORDSTRASSE 2 city: BONN postcode: 53111 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BONN)	coordinator	191˙875.00
2	CUSTODIX NV CUSTODIX NV Organization address address: KORTRIJKSESTEENWEG 214 b3 city: SINT-MARTENS-LATEM postcode: 9830 website: www.custodix.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (SINT-MARTENS-LATEM)	participant	299˙625.00
3	HEALTH PRODUCTS REGULATORY AUTHORITY HEALTH PRODUCTS REGULATORY AUTHORITY Organization address address: EARLSFORT CENTRE BLOCK A KEVIN O MALLEY HOUSE EARLSFORT TERRACE city: DUBLIN postcode: 2 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (DUBLIN)	participant	110˙625.00
4	HL7 INTERNATIONAL FONDATION HL7 INTERNATIONAL FONDATION Organization address address: SQUARE DE MEEUS 38-40 city: BRUSSELS postcode: 1000 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUSSELS)	participant	90˙313.00
5	SIEC BADAWCZA LUKASIEWICZ INSTYTUTLOGISTYKI I MAGAZYNOWANIA SIEC BADAWCZA LUKASIEWICZ INSTYTUTLOGISTYKI I MAGAZYNOWANIA Organization address address: UL ESTKOWSKIEGO 6 city: POZNAN postcode: 61-755 website: www.ilim.poznan.pl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PL (POZNAN)	participant	87˙625.00
6	REGIONE LOMBARDIA REGIONE LOMBARDIA Organization address address: PIAZZA CITTA DI LOMBARDIA 1 city: MILANO postcode: 20124 website: www.regione.lombardia.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (MILANO)	participant	80˙625.00
7	AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS Organization address address: c/ Campezo Edificio 8 1 city: MADRID postcode: 28022 website: http://www.aemps.gob.es/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (MADRID)	participant	74˙375.00
8	STICHTING KONINKLIJK NEDERLANDS NORMALISATIE INSTITUUT STICHTING KONINKLIJK NEDERLANDS NORMALISATIE INSTITUUT Organization address address: VLINDERWEG 6 city: DELFT postcode: 2623 AX website: www.nen.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (DELFT)	participant	62˙875.00

Map

Project objective

The CSA will enhance the safety of cross-border healthcare through interoperable ePrescriptions. epSOS solved the message transfer problem, but encountered 2 serious “delivery” problems: the univocal identification of medicinal products (MPs) dispensed abroad, and substitution challenges. Global SDOs (WHO, HL7, IHTSDO, ISO/CEN, GS1), EU regulatory agencies (EMA), MS Competent Authorities, major stakeholders (industry, health professionals, patients) harmonise their related efforts to deliver • common data models - expanding upon epSOS and existing standards (ISO/IDMP) - for prescribed MPs • a common meta-vocabulary for unambiguous definition, description, and identification of MPs • rules to harmonise practices of therapeutic and economic substitution • a roadmap for post-project actions and implementations • policy recommendations for the EU-USA road mapping process (MoU) Work will link to related research & innovation activities of SDOs, epSOS, policy and regulatory processes (eHealth Network), the three other PHC34 projects. WP1 develops a concise conceptual framework, including use case scenarios where the identification of a MP is an issue, including pharmacological and pharmacokinetic attributes, clinical indications and risks. WPs 2 address the identification and description of the pharmaceutical products, considering implementability as essential. WP3 investigates the situation in MSs with respect to substitution, and explores options for substitution. Each track develops a set of concrete solutions and road map recommendations, validated by experts in F2F meetings and workshops in WP4. Fostering exploitation by MS regulatory agencies and communication of results is the duty of WP5. The project involves national competent authorities, SDOs and stakeholders not part of the core team at an early stage to assure the practicability, acceptance and trust in the solutions developed. The CSA lasts 2 years involving 8 beneficiaries and about 25 expert organisations.

Deliverables

List of deliverables.
D6.1 1st annual report on the activities of the Expert Council	Documents, reports	2019-07-23 09:11:13
D2.1 Report on standards based identification and description enabling dispensing equivalent medicinal products	Documents, reports	2019-07-23 09:11:14
D1.2 Complementary uses cases	Documents, reports	2019-07-23 09:11:14
D1.1 epSOS identification/description problems	Documents, reports	2019-07-23 09:11:14
D2.3 openMedicine final identifying and descriptive attributes	Documents, reports	2019-07-23 09:11:14
D8.2 openMedicine portal online	Websites, patent fillings, videos etc.	2019-07-23 09:11:14
D5.2 openMedicine substitution: options and roadmap	Documents, reports	2019-07-23 09:11:13
D5.1 Meeting the substitution challenge: Member State regulations and core cross-border issues	Documents, reports	2019-07-23 09:11:13
D7.1 Communication Plan	Documents, reports	2019-07-23 09:11:13
D6.2 Report on validation activities	Documents, reports	2019-07-23 09:11:13
D1.3 Initial openMedicine infostructure	Documents, reports	2019-07-23 09:11:14
D7.2 1st Communication and Liaison Report	Documents, reports	2019-07-23 09:11:14
D7.3 2nd Communication and Liaison Report	Documents, reports	2019-07-23 09:11:14
D6.4 2nd annual report on the activities of the Expert Council	Documents, reports	2019-07-23 09:11:14
D6.3 openMedicine Recommendations and Roadmap for Implementation	Documents, reports	2019-07-23 09:11:13
D2.2 Comprehensive set of openMedicine identifying and descriptive attributes of medicinal products and the available standards	Documents, reports	2019-07-23 09:11:14

Take a look to the deliverables list in detail: detailed list of openMedicine deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OPENMEDICINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OPENMEDICINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.5.)

EUCANCan (2019)

EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.

Read More

iReceptor Plus (2019)

ARCHITECTURE AND TOOLS FOR THE QUERY OF ANTIBODY AND T-CELL RECEPTOR SEQUENCING DATA REPOSITORIES FOR ENABLING IMPROVED PERSONALIZED MEDICINE AND IMMUNOTHERAPY

Read More

Instand-NGS4P (2020)

Integrated and standardized NGS workflows for Personalised therapy

Read More